Streetbeat News

Stock Prices

WMT

Walmart reported better-than-expected Q2 earnings and raised its FY24 outlook, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 11:07 am

MULN

Mullen Automotive has announced the commencement of its $25 million stock buyback program.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 11:06 am

WMT

Walmart has increased its FY24 revenue growth outlook from 3.5% to 4% - 4.5%, compared to the previous estimate of $636.44B.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 11:06 am

PLCE

Children's Place has revised its FY23 sales guidance from a range of $1.575B - $1.590B to $1.575B - $1.585B, which is still above the estimated $1.56B.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 11:06 am

WMT

Walmart has reported that food is a strong sector for them, but they are also seeing encouraging results in general merchandise compared to their expectations at the start of the quarter. The company also stated that they are in a good position with their inventory for the second half of the year.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 11:05 am

WMT

Walmart's Q2 inventory has decreased by 7.6%.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 11:04 am

WMT

Walmart has released its Q3 outlook, predicting an adjusted EPS of $1.45-$1.50, compared to the $1.49 estimate. The company also expects a revenue growth of 3%, versus the $156.65 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 11:04 am

SPTN

SpartanNash has reduced its FY23 total net sales outlook from $9.90B-$10.20B to $9.65B-$9.95B, which is below the consensus estimate of $10.01B.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 11:04 am

AMRN

INDP

RPID

TSHA

Insiders at Taysha Gene Therapies, Amarin Corporation, Rapid Micro Biosystems, and Indaptus Therapeutics have recently made significant purchases of their companies' stocks. Taysha Gene Therapies reported initial clinical data from the first adult Rett Syndrome patient dosed in the REVEAL Phase 1/2 trial and announced $150 million private placement financing. Amarin posted a profit for the second quarter. Rapid Micro Biosystems and Indaptus Therapeutics posted narrower-than-expected quarterly losses.

Portfolio Pulse from Lisa Levin

August 17, 2023 | 11:03 am

WMT

Walmart has increased its FY2024 adjusted EPS guidance from $6.10-$6.20 to $6.36-$6.46, which is higher than the estimated $6.27.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 11:02 am